| Funding Opportunity ID: | 331382 |
| Opportunity Number: | W81XWH-21-OCRP-CTRA |
| Opportunity Title: | CDMRP Ovarian Cancer Clinical Translational Research Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | |
| Funding Instrument Type: | Cooperative Agreement
Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | |
| CFDA Number(s): | 12.420 |
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | |
| Agency Code: | DOD-AMRAA |
| Agency Name: | Department of Defense
Dept. of the Army — USAMRAA |
| Posted Date: | Feb 08, 2021 |
| Close Date: | Jul 08, 2021 |
| Last Updated Date: | Feb 08, 2021 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
| Estimated Total Program Funding: | $2,880,000 |
| Expected Number of Awards: | 4 |
| Description: | The Clinical Translational Research Award is intended to support correlative studies that are associated with a clinical trial. The translational research should address high-impact or unmet needs in ovarian cancer. Applications focused on the following OCRP priority are encouraged to apply:* Utilize precision medicine and computational approaches that identify individual tumor characteristics and predictive biomarkers across diverse groups to optimize patient care and outcomesAlthough not intended to fund the operational aspects of clinical trials, this award supports research projects related to or associated with planned, ongoing, or completed clinical trials supported by other funding sources. Projects that develop clinical endpoints for clinical trials are also encouraged. The application must demonstrate availability and accessibility of the appropriate human subject population, specimens, or human-based resources. The application should also provide a detailed statistical analysis plan that includes a power analysis reflecting sample size projections that will allow a meaningful outcome. Preclinical studies in animals are not allowed. |
| Version: | 1 |
